
1211443-61-6
Product name: 2-chloro-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamideCAS:1211443-61-6. MF:C14H17ClN4O. MW:292.76. EINECS:808-234-2. MDL No.:MFCD20527881
Add to Inquiry![CAS 643068-20-6 | 6-Oxabicyclo[3.2.1]octan-7-one, 4-bromo-, (1R,4S,5R)-](/uploads/41320/small/cas-643068-20-6-d8ec5.jpg)
CAS 643068-20-6 | 6-Oxabicyclo[3.2.1]octan-7-one, 4-bromo-, (1R,4S,5R)-
Name: 6-Oxabicyclo[3.2.1]octan-7-one,4-bromo-,(1R,4S,5R)-MF: C7H9BrO2MW: 205.05CAS: 643068-20-6
Add to Inquiry
CAS 61393-07-5 | 5-ethenyl-2-hydroxybenzoic Acid
Name: Benzoic acid, 5-ethyl-2-hydroxyl-CAS number: 61393-07-5Molecular formula: C9H8O3Molecular weight: 164.16EINECS number:MDL No.:
Add to Inquiry
CAS 40337-66-4 | 4-(3-Bromopropyl)pyridine
Name: 4-(3-BROMO-POPYL)-PAYRIDINECAS number: 40337-66-4Molecular formula: C8H10BrNMolecular weight: 200.08EINECS number:MDL No.:MFCD07785861
Add to Inquiry
431-47-0 METHYL TRIFLUOROACETATE
Product name: Methyl trifluoroacetateCAS number: 431-47-0Molecular formula: C3H3F3O2Molecular weight: 128.05EINECS number: 207-074-5
Add to Inquiry
843666-27-3
Product name: 16-(Tert butoxy)-16-oxohexadecanoic acidCAS number: 843666-27-3Molecular formula: C20H38O4Molecular weight: 342.51EINECS number:MDL No.:MFCD23136039
Add to Inquiry
1446013-08-6 Fmoc-His-AiB-OH TFA
Product name: Fmoc His Aib OH TFACAS number: 1446013-08-6Molecular formula: C27H27F3N4O7Molecular weight: 576.53EINECS number: 815-122-7MDL No.:
Add to Inquiry
475086-75-0
Product name:4-((5,6-Diphenylpyrazin-2-yl)(isopropyl)amino)butan-1-olCAS:475086-75-0. MF:C23H27N3O. MW:361.48. EINECS:813-799-3. MDL No.:MFCD28411750
Add to Inquiry
134877-43-3
CAS:134877-43-3. MF:C20H18F2O8S. MW:456.41. EINECS:1312995-182-4. MDL No.:MFCD22422479
Add to Inquiry

17025-47-7 Phenyl Tribromomethyl Sulfone
CAS:17025-47-7. MF:C7H5Br3O2S. MW:392.89. EINECS:241-096-6. MDL No.:MFCD00060068
Add to Inquiry
225378-53-0
Product name:2-(2-(tert-Butyl)-6-methyl-4H-pyran-4-ylidene)malononitrileCAS:225378-53-0. MF:C13H14N2O. MW:214.26. EINECS:. MDL No.:MFCD07773066
Add to Inquiry
China Ribociclib intermediate Manufacturers Factory Suppliers
We will make just about every exertion for S N 2 3 Epoxypropyl phthalimide, intermediate commercial products, niche market intermediate .The company provides products with high performance and price ratio, and has accumulated rich experience in Ribociclib intermediate on-demand customization. In our company, customer satisfaction is the core of our culture, which drives everything we do and ensures that customers' needs are met excellently. The company always adheres to the production principle of quality first and does not ignore any quality problems. We strive to exceed our clients' expectations by providing exceptional service and value. Meeting and surpassing the needs of consumers is the direction and goal of our struggle, and also our motivation. We have not only gained the favor of consumers, but also won the recognition of many international organizations. Our team of experts is dedicated to providing the highest level of customer service and support.WEBMar 14, 2023 · Harbeck N, Gluz O, Christgen M, Braun M, Thill M, Wimberger P, et al. Adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus...
WEBMay 22, 2018 · Ribociclib is a specific cyclin dependent kinase (Cdk) 4/6 inhibitor that induces G 1 arrest by blocking the formation of cyclin D1-Cdk4/6 complex and inhibiting retinoblastoma...
WEBKisqali (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6...
WEBJun 2, 2022 · Definition of intermediate-risk is either based on Oncotype DX and endocrine responder status (measured by Ki67-response after 2-4 weeks of induction endocrine therapy (ET)) or on...
WEBMar 16, 2022 · Ecofriendly Synthesis of Ribociclib Intermediate Using Regioselective Hydrodechlorination and DMAP Catalyzed Ester Hydrolysis. March 2022. Topics in Catalysis 65 (1) DOI:......
WEBMay 25, 2020 · It investigates whether patients (pts.) with HR+/HER2- EBC identified during screening as intermediate risk (based on Oncotype DX and response to 3 weeks of preoperative endocrine...
